Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What’s intriguing about the SP is that eliminates the “chopstick”effect associated with normal SIL’s procedures.
Something that even the multiport Alf experiences if trocars are placed incorrectly. By the way, Davinci Xi targets anatomy during docking and along with articulation eliminates that issue.
Already shorted it on Friday.
Nailed it!
Your quote. “LOL! White DingDong e-RAG?? That is what they get paid to do- “
Yes, you did say that. I’m confusing nothing and have been spot on with trxc since stalling SB rejection 3 days before fda denial and a pps that tankard to .50.
Message me
You failed to prove your point. You claim was that they are paid, your post says nothing about them being paid. It says they and they’re clients have a short position. You’re confusing the facts.
Get someone to write a long thesis about senhance and TRXC.
They can’t.
Nope. WD has Pope and TRXC pegged as do I. They’re paid nothing and do their own DD. I know.
Old report
Nonsense is exactly what you just “spouted”when asked how Alf benefits the patient. Something you can’t answer and surgeons ask before even look at at a medical device.
Btw. The PPS is down 15%in 3 days.
If you didn’t care you wouldn’t reply. The stock is based on the technology, you can’t separate the two. If the tech doesn’t sell to stock will collapse. Period.
To date, the 9 year old outdated platform has yet to experience a commercial sale.
Just like the FDA approved Spider, Alf will be shelved.
Heard it from a rep
Stock Twits is now complicit in a TRXC Pump and Dump. They “suspend”those that post valid data to provide nothing but pumping without just cause.
TRXC is going to tank, just like it did in 2014, 2016. Pope will be sued and it’s coming.
JnJ is 1/2 of VERB Surgical. What Pope is doing is a scam.
I’m all fairness I heard of a buyout!
Can’t say how or why. I don’t like senhance. But I heard covidian might buy our TRXC. Unfreakin believable!
Pope Scams Investors
How many retail suckers buy into Pope propaganda?
Too many.
After all of Popes BS answer on simple question....
How does senhance (previously named “ALF”). ...
Benefit Patient outcomes?
Simple question.
Tell that to those that have been holding since $6.00 way back in 2014. ????
Post the escrow account! I can provide it if you don’t know how.
Let’s do this!
LOL. It’s been DOWN 500% 3 TIMES since 2014.
Anyone holding should buy more! Average down!
Still waiting fo a answer ZACK
Yet you can’t state how Alf benefits the patient and why it doesn’t sell. Pope needs 70 sales per quarter to break EVEN.
They haven’t sold ONE COMMERCIALLY.
3mm? Why?
It offers no patient benefits when surgical times remain excessive due to Alfs lack of articulation, counter traction, massive OR footprint, 6% conversion rate, longer hospitalization times and excessive costs to the patient and hospitals.
3MM has been around for decades in pediatrics yet never adapted to adult procedures. Why? It has no benefits to the patient but Pope makes retail suckers think it does.
It’s not “scarless” anymore than a 8mm incision closed with 4-0 Monocryl suture.
Zack the cable guy!
How many Senhance platforms are being used commercially sine CE approval in 2013?
Open a escrow account. Place your bet. I’m happy to go 10K +
Have them contact me.
In 2020 senhance sits next to SPIDER.
Place your bet.
And what good is it when Transenterix’s alf in 2009 technology?
More scam.
Well then show the submitted paperwork. Waiting......
Wait for VERB Surgical they have J&J medical with Google Dollars.
That’s the next competition.
Blinders are those worn by TRXC investors
And it’s a damn shame. 95% of people in a OR have no clue as to how Robotic Surgical procedures are preformed, yet 100% of TRXC investors seem to know.. Hilarious! Keep buying what Pope tells you, just like Surgibot, Senhance (a renamed ALF) will fail. Anyone remember SPIDER? THat was FDA approved as well. It failed to sell because it didn’t benefit the patient.
You’re welcome to post how ALF (renamed Senhance) can provide better patient outcomes.....
Here’s the facts....
J Minim Invasive Gynecol. 2016 Sep-Oct;23(6):933-8. doi: 10.1016/j.jmig.2016.05.008. Epub 2016 May 28.
Total Laparoscopic (S-LPS) versus TELELAP ALF-X Robotic-Assisted Hysterectomy: A Case-Control Study.
Fanfani F1, Restaino S2, Rossitto C3, Gueli Alletti S3, Costantini B3, Monterossi G3, Cappuccio S3, Perrone E3, Scambia G3.
Author information
Abstract
STUDY OBJECTIVE:
To compare the feasibility and safety of the TELELAP ALF-X system and standard laparoscopy for total hysterectomy to treat patients with benign and early malignant gynecologic disease.
DESIGN:
Single-institution retrospective case-control study (Canadian Task Force classification II-2).
SETTING:
Catholic University of the Sacred Heart, Rome, Italy.
PATIENTS:
Between October 2013 and May 2015, 203 women underwent TELELAP-ALF X (group 1) or standard laparoscopic (group 2) total hysterectomy and were enrolled.
INTERVENTIONS:
Total standard laparoscopy vs TELELAP ALF-X robot-assisted hysterectomy for benign and early malignant gynecologic disease.
MEASUREMENTS AND MAIN RESULTS:
In group 1, the median age was 55 years (range, 40-79 years), median body mass index (BMI) was 25 kg/m(2) (range, 17-38 kg/m(2)), and 51 patients (58%) had undergone previous abdominal surgery. In the control group, the median age was 55 years (range, 34-90 years), median BMI was 25 kg/m(2) (range, 17-41 kg/m(2)), and 31 patients (27%) had previous abdominal surgery. The median operative time was 147 minutes (range, 58-320 minutes) in group 1 and 80 minutes (range, 22-300 minutes) in group 2 (p = .055). The median estimated blood loss was 57 mL (range, 0-600 mL) in group 1 and 99 mL (range, 0-400 mL) in group 2, with no significant differences between the 2 groups (p = .963). Procedures were successfully performed without conversion in 94.3% of cases in the group 1 and in all cases in group 2. Early postoperative pain was significantly lower in group 2.
Nope. RASD CSTFA. And you can’t even figure that out.
So you’re clueless. I don’t do surgery? When was the last time you were in a case? I assist in tissue dissection and excise viscera during RASD procedures. If I fail to do my job the patient gets hurt. Ureteral dissection is just as much my responsibility as it is the surgeons. If I blow it, where calling in a urologist.
This is exactly why Pope conns retail investors and yes, you are clueless.
No. The PPS has stopped once again until Pope delivers. Just like 2014,2016...the PPS will go under a dollar.
Nope. I do RASD Surgery for a living and know for a fact Alf isn’t viable. Prove me wrong. How does Alf benefit the patient va existing technology?
You avoided the question once again. Let me repeat it. Try to keep up.......
How does ALF provide better patient outcomes?
Those 146 institutions get it Wrong all of the time. The majority are index funds that automatically add. Their positions are less than half a point. Peanuts.
Here’s an idea. The next time you or a family member needs surgery, ask a fund manager to do it. See ya, I’m off to ask my surgeon about investment advice.
Nope. No vested interest. I know better.
I post ALL clinical data. Not old, not new, ALL of it.
Moot point anyway, pope changed nothing about the platform that would increase times. He just pumps new features to avoid what he can’t change. And those “new features”, energy, 3mm only catch Alf up to 2010. That tech may be new to you but not to the surgical community.
A old 1950’s Chevy driving 55 goes no faster than a 2018 Chevy driving 55.
Anyone which a clue about surgical technique knows counter traction is necessary for tissue dissection. That requires 4 arms
Every study used 4 arms, Alf was designed with 4 arms, Alf was CE cleared in Europe with 4 arms.
Alf is pictured with 4 arms.
Pops says, oh, let’s just submit 3 arms. LOL.
Alf was submitted with 4 arms weather you want to admit it or not.
nope. The Alf average time were based on over 200 procedures and the 20 Minute Davinci times are a 2 year average of thousands.
The FDA didn’t approve senhance as submitted. They approved 3 arms and now it can’t counter tract,
I want ONE PERSON to state how Senhance benefits patient outcomes.
Just one.
Davinci Xi does a tahbso in 20 Minutes, Alf takes 147. Explain it.
Alf (renamed Senhance by Pope) takes 147 minutes to do this. Prove me wrong.
Hilarious! You proved my point. Cramer was the reason to buy. You need to keep up BULLER! Hilarious! Now tell me why Alf benefits the patient
Simple question.
How does senhance benefit the patient?